What we do
We have built our AI-enabled drug discovery engine, the Benevolent Platform™, to drive a revolution in drug discovery – from target identification through to clinical development.
THE BENEVOLENT PLATFORM™
A versatile, scalable and proven AI drug discovery engine
Comprehensive data foundations
We integrate data from across domains and data types, including ’omics, molecules, experiments, literature, pathology and biological systems to provide a holistic view of biology.
Biology first
Our technology empowers scientists to access an ever-expanding data landscape and map the underlying biology of complex multifactorial diseases in unprecedented detail.
Hypothesis driven
Scientists use our tools to navigate disease networks to gain a comprehensive understanding of biological effects, refine hypotheses and predict high-confidence targets.
WET LABS AND AI CHEMISTRY
AI chemistry and in-house wet labs reduce development timelines
We can validate high-quality drug targets generated by the Benevolent Platform™ in our fully equipped laboratories in Cambridge (UK), where we have cutting-edge technologies such as CRISPR, RNA-seq and human iPSCs to evaluate target hypotheses in cell-based models.
BENEFITS
Proven to enhance drug discovery
We can work on any therapeutic area due to the breadth and diversity of our data foundations.
The Benevolent Platform™ can be applied to antibody and biologic targets, in addition to small molecule targets, to further diversify our portfolio.
Our predictive tools can surface targets that have never been considered for a disease before – and spark creativity in scientists.
Through the combined capabilities of our AI Platform, scientific expertise and wet lab facilities we can rapidly identify and validate targets and reduce drug development timelines.
Our scalable, repeatable approach can support multiple in-house drug programmes and commercial collaborations.
Scientists use our tools to build higher confidence hypotheses in the earliest stages of drug discovery, with the aim of reducing costly failures down the line.